Validation of the electronic Psoriasis Area and Severity Index application: Establishing measurement equivalence - 27/07/19
Doi : 10.1016/j.jaad.2019.04.073
Faraz Mahmood Ali, MBChB, MRCP a, ⁎ 
, Sam Salek, PhD, RPh b, c, Andrew Y. Finlay, MBBS, FRCP a, Vincent Piguet, MD, PhD, FRCP a, d
, Sam Salek, PhD, RPh b, c, Andrew Y. Finlay, MBBS, FRCP a, Vincent Piguet, MD, PhD, FRCP a, d a Division of Infection and Immunity, Department of Dermatology and Academic Wound Healing, School of Medicine, Cardiff University, Cardiff, United Kingdom
b School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom
c Institute for Medicines Development, Cardiff, United Kingdom
d Division of Dermatology, Department of Medicine, University of Toronto, and Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada
∗Correspondence to: Faraz Ali, MBChB, MRCP, Department of Dermatology, Division of Infection and Immunity, School of Medicine, Cardiff University, 3rd Floor Glamorgan House, Heath Park, Cardiff CF14 4XN, UKDepartment of DermatologyDivision of Infection and ImmunitySchool of MedicineCardiff University3rd Floor Glamorgan House, Heath ParkCardiffCF14 4XNUK
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Saturday 27 July 2019
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
| Funding sources: The study was supported by a research grant from Janssen-Cilag Limited. |
|
| Conflicts of interest: Dr Ali has received travel expenses for attending American Academy of Dermatology meetings from Janssen-Cilag Limited and has received lecture fees from Leo Pharmaceuticals. Dr Finlay is joint copyright owner of the Dermatology Life Quality Index, and he and Cardiff University receive royalties. Dr Finlay is a member of a Novartis advisory board and has received lecture fees and travel expenses from Novartis. Dr Piguet undertakes personal advisory work for Pfizer, AbbVie, Janssen, UCB, Novartis, Almirall, and Celgene and has received departmental support from AbbVie, Bausch Health, Celgene, Janssen, LEO Pharma, Lilly, NAOS, Novartis, Pfizer, Pierre Fabre, and Sanofi. Dr Salek has no conflicts of interest to disclose. |
© 2019
Publié par Elsevier Masson SAS.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?